UBS Asset Management Americas Inc. Sells 144,120 Shares of Alnylam Pharmaceuticals Inc. (ALNY)
UBS Asset Management Americas Inc. lowered its stake in Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 8.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,518,762 shares of the biopharmaceutical company’s stock after selling 144,120 shares during the period. UBS Asset Management Americas Inc. owned about 1.77% of Alnylam Pharmaceuticals worth $102,943,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Schroder Investment Management Group increased its position in shares of Alnylam Pharmaceuticals by 235.0% in the second quarter. Schroder Investment Management Group now owns 18,592 shares of the biopharmaceutical company’s stock valued at $1,032,000 after buying an additional 13,042 shares during the last quarter. Turner Investments L.P. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $575,000. Renaissance Technologies LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $13,433,000. CIBC Asset Management Inc increased its position in shares of Alnylam Pharmaceuticals by 1.1% in the second quarter. CIBC Asset Management Inc now owns 4,119 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 46 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock worth $298,843,000 after buying an additional 182,614 shares in the last quarter. 89.81% of the stock is currently owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded down 2.88% during trading on Monday, hitting $46.50. The stock had a trading volume of 421,822 shares. The company’s market capitalization is $3.99 billion. The stock’s 50-day moving average price is $39.69 and its 200-day moving average price is $59.81. Alnylam Pharmaceuticals Inc. has a 1-year low of $31.38 and a 1-year high of $109.10.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.14) by $0.07. The firm had revenue of $13.70 million for the quarter, compared to analyst estimates of $9.14 million. Alnylam Pharmaceuticals had a negative net margin of 1,041.16% and a negative return on equity of 33.97%. The firm’s quarterly revenue was up 116.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.91) EPS. Analysts expect that Alnylam Pharmaceuticals Inc. will post ($4.81) earnings per share for the current year.
A number of research analysts have recently issued reports on ALNY shares. Leerink Swann reissued a “market perform” rating and issued a $43.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 10th. JPMorgan Chase & Co. downgraded Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $83.00 to $51.00 in a research note on Thursday, October 6th. FBR & Co reissued an “outperform” rating and issued a $180.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 27th. Zacks Investment Research raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Tuesday, October 25th. Finally, Jefferies Group dropped their price objective on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research note on Thursday, October 6th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Buy” and an average target price of $68.63.
In other news, Director David E. I. Pyott purchased 27,900 shares of the company’s stock in a transaction that occurred on Thursday, October 13th. The shares were bought at an average price of $37.00 per share, for a total transaction of $1,032,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.00% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.